Boston Scientific Corporation

NYSE:BSX 주식 리포트

시가총액: US$64.8b

Boston Scientific 향후 성장

Future 기준 점검 1/6

Boston Scientific (는) 각각 연간 9.6% 및 7.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.1% 로 예상됩니다.

핵심 정보

9.6%

이익 성장률

9.19%

EPS 성장률

Medical Equipment 이익 성장17.2%
매출 성장률7.6%
향후 자기자본이익률18.10%
애널리스트 커버리지

Good

마지막 업데이트17 Jul 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jul 14

BSX: Reset Growth Expectations Will Set Stage For Future Recovery Potential

Analyst price targets for Boston Scientific have been revised downward by roughly $25 to $30 as analysts factor in softer Watchman growth, ongoing electrophysiology headwinds, and slightly more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Boston Scientific points to a mixed but still constructive backdrop, with many firms trimming price targets while maintaining positive ratings.
Seeking Alpha • Jul 06

Boston Scientific: The Time Has Come To Catch This Falling Knife

Summary Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%. With a $4.0 billion free cash flow guidance, BSX currently trades at an FCF yield of approximately 6.0%, which is one of the highest in the company's history. Given where the stock is trading, I am encouraged by the $2.0 billion accelerated share repurchase program announced last May. It is quite unusual for Boston Scientific to aggressively repurchase its own shares, as we have to go all the way back to fiscal 2020 to find the last share repurchases. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 30

BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds

The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.
분석 기사 • Jun 19

Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance

Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...
내러티브 업데이트 • Jun 16

BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations

Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.
내러티브 업데이트 • Jun 01

BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations

Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.
내러티브 업데이트 • May 08

BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations

Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
새로운 내러티브 • Apr 24

Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead

Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Apr 22

BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns

Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.
새로운 내러티브 • Apr 08

Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes

Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Apr 07

BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns

Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.
내러티브 업데이트 • Mar 24

BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines

Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.
내러티브 업데이트 • Mar 08

BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound

Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.
내러티브 업데이트 • Feb 22

BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize

Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.
내러티브 업데이트 • Feb 06

BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize

The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
새로운 내러티브 • Jan 25

BSX after Penumbra ?

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.
내러티브 업데이트 • Jan 10

BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential

Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.
내러티브 업데이트 • Dec 25

BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan

Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.
내러티브 업데이트 • Dec 11

BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum

Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.
내러티브 업데이트 • Nov 27

BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum

Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.
내러티브 업데이트 • Nov 07

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.
내러티브 업데이트 • Oct 24

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.
Seeking Alpha • Mar 18

Boston Scientific: Bright Future, Rather Pricey

Summary A diversified portfolio, strategic acquisitions, and aggressive R&D have driven Boston Scientific's recent revenue and EPS growth, outpacing peers like Abbott and Medtronic. Consequently, BSX stock is trading at a significant premium, reflecting high investor optimism. Intense competition along with regulatory and safety concerns also remain key challenges. While Boston's fundamentals suggest that double-digit earnings growth can be sustained, there may be little margin for error at the current stock price. I recommend a Hold at ~$97. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:BSX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202825,2284,7275,1026,21821
12/31/202723,3244,1334,0325,41628
12/31/202621,5733,9404,1415,02527
3/31/202620,6143,5653,4754,341N/A
12/31/202520,0742,8983,6584,534N/A
9/30/202519,3492,7913,8444,626N/A
6/30/202518,4942,5053,5054,285N/A
3/31/202517,5542,0323,0143,812N/A
12/31/202416,7471,8532,6453,435N/A
9/30/202415,9111,7932,1632,936N/A
6/30/202415,2291,8281,8552,632N/A
3/31/202414,7071,7651,7192,477N/A
12/31/202314,2401,5701,7922,503N/A
9/30/202313,7571,1911,7362,353N/A
6/30/202313,4008611,5592,125N/A
3/31/202313,0458461,2561,774N/A
12/31/202212,6826421,0081,526N/A
9/30/202212,5675966291,197N/A
6/30/202212,3298286681,192N/A
3/31/202212,1627541,0071,528N/A
12/31/202111,8889851,3981,870N/A
9/30/202111,4701,1011,7012,065N/A
6/30/202111,1965261,9392,243N/A
3/31/202110,1222011,6041,869N/A
12/31/20209,913-1151,2191,508N/A
9/30/202010,1083,6851,2421,527N/A
6/30/202010,1573,9801,0081,386N/A
3/31/202010,7854,2879861,409N/A
12/31/201910,7354,700N/A1,836N/A
9/30/201910,3921,090N/A1,163N/A
6/30/201910,0771,396N/A1,162N/A
3/31/20199,9371,797N/A467N/A
12/31/20189,8231,671N/A310N/A
9/30/20189,670670N/A975N/A
6/30/20189,500521N/A926N/A
3/31/20189,267112N/A1,626N/A
12/31/20179,048104N/A1,426N/A
9/30/20178,831843N/A1,418N/A
6/30/20178,714788N/A935N/A
3/31/20178,582435N/A1,059N/A
12/31/20168,386347N/A1,182N/A
9/30/20168,09581N/A835N/A
6/30/20167,878-345N/A1,274N/A
3/31/20167,595-36N/A913N/A
12/31/20157,477-239N/A691N/A
9/30/20157,314-396N/A711N/A

애널리스트 향후 성장 전망

수입 대 저축률: BSX 의 연간 예상 수익 증가율(9.6%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: BSX 의 연간 수익(9.6%)이 US 시장(17.3%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: BSX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BSX 의 수익(연간 7.6%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: BSX 의 수익(연간 7.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: BSX의 자본 수익률은 3년 후 18.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/24 22:30
종가2026/07/24 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Boston Scientific Corporation는 58명의 분석가가 다루고 있습니다. 이 중 28명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jasper HellwegArgus Research Company
David RescottBaird
null nullBaird